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Objective: The effects of a new long-term subcutaneous vascular access device were studied in access-challenged patients
who were poor candidates for fistulas or grafts due to venous obstruction. Bacteremia rates, patency, and function of the
Hemodialysis Reliable Outflow (HeRO) Vascular Access Device (Hemosphere Inc, Minneapolis, Minn) were evaluated.
Methods: The HeRO device consists of a 6-mm expanded polytetrafluoroethylene graft attached to a 5-mm nitinol-
reinforced silicone outflow component designed to bypass venous stenoses and enter the internal jugular vein directly,
providing continuous arterial blood flow into the right atrium. The HeRO device was studied in a multicenter clinical
trial to test the hypothesis that access-challenged patients would experience a statistically significant reduction in
bacteremia rates compared with a tunneled dialysis catheter (TDC) literature control of 2.3/1000 days. HeRO-related
bacteremia rates, adequacy of dialysis, patency, and adverse events were analyzed.
Results: The HeRO device was implanted in 36 access-challenged patients who were followed for a mean 8.6 months (9931
HeRO days). The HeRO-related bacteremia rate was 0.70/1000 days. All HeRO-related bacteremias occurred during the
bridging period when a TDCwas still implanted before HeRO graft incorporation. HeRO adequacy of dialysis (mean Kt/V)
was 1.7. HeRO primary patency was 38.9%, and secondary patency was 72.2%.
Conclusions: In access-challenged patients, a statistically significant reduction in HeRO-related bacteremia was noted
compared with TDC literature. The device had similar function and patency compared with conventional arteriovenous
graft literature. ( J Vasc Surg 2009;50:600-7.)Tunneled dialysis catheters (TDCs) are considered the
vascular access of last resort when all other options for
arteriovenous fistulas (AVFs) and grafts (AVGs) have been
exhausted. TDCs are associated with an increased incidence
of bacteremia, thereby leading to higher morbidity and
mortality that results in significantly increased hospital
costs.1 TDCs are also associated with less effective dialysis
due to reduced blood flow rates, frequent malfunctions,
and the development of central venous stenosis.
Despite these disadvantages, and considering the rela-
tive success of the National Kidney Foundation Kidney
Dialysis Outcome Quality Initiative (KDOQI)2 and the
From the Departments of Surgery at University of Miami Hospital, Miamia;
Southern Illinois University, Springfieldb; Bamberg County Hospital,
Bambergc; Sentara Heart Hospital, Norfolkd; The Methodist Hospital,
Houstone; and Duke Medical Center, Durham.f
This study was sponsored by Hemosphere Inc, to collect safety and efficacy
data in support of a 510(k) submission to the Food and Drug Adminis-
tration seeking market clearance for the HeRO Vascular Access Device.
All of the authors’ institutions were compensated by Hemosphere for
conducting the study.
Competition of interest: Marc H. Glickman, MD, and John R. Ross, were
paid consulting fees during the product development period, which have
since ceased as of 2007.
Additional material for this article may be found online at www.
jvascsurg.org.
Reprint requests: Howard E. Katzman, MD, University of Miami Hospital,
1321 NW 14th St, Ste 306, Miami, FL 33125 (e-mail: hkatzman4@
comcast.net).
0741-5214/$36.00
Copyright © 2009 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2009.04.014
600Fistula First movement,3 the number of patients undergo-
ing dialysis with TDCs continues to increase. The 2007
End-Stage Renal Disease Clinical Performance Measures
Project (ESRD CPM Project) reported a 58% growth in
catheter usage between 2002 and 2006 in the access-
challenged population.4 Many of these patients likely re-
quire catheters for dialysis because venous obstruction
makes them ineligible for the benefits of a long-term sub-
cutaneous AV access option.
A new long-term subcutaneous AV access, the Hemo-
dialysis Reliable Outflow (HeRO) Vascular Access Device
(Hemosphere Inc, Minneapolis, Minn), was approved by
the United States Food and Drug Administration (FDA) as
a graft for use in ESRD patients in whom peripheral venous
access sites suitable for traditional fistulas or grafts have
been exhausted. This study evaluated bacteremia rates,
patency, and function of the HeRO device in the access-
challenged patient population.
METHODS
Device description. The HeRO device is a standard
6-mm inner diameter expanded polytetrafluoroethylene
(ePTFE) graft attached to a 5-mm inner diameter nitinol-
reinforced silicone outflow component. The device is de-
signed such that the ePTFE is placed in the upper arm over
the biceps muscle. The silicone outflow component is
placed similar to a TDC, and by way of a counter incision at
the deltopectoral groove, the two components are brought
together entirely subcutaneously with a titanium connec-
-sided
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placed in the right atrium (Figs 1 and 2). Therefore, the
device provides continuous arterial blood flow into the
central venous system, forming a subcutaneous AV access
that bypasses central venous stenosis and the need for a
graft-to-vein anastomosis. The device can be placed in the
right or left upper extremity, depending on the venous
anatomy and presence of outflow obstruction.
Study design and end points. Enrollment in this
prospective, United States, multicenter, nonrandomized
study of access-challenged patients commenced in March
2006. The primary end point was bacteremia related to the
HeRO device and the implant procedure. Secondary end
points included serious adverse events related to the device
and the implant procedure, need for subsequent interven-
tions and adequacy of dialysis including urea reduction
ratio (URR) and Kt/V, where K is dialyzer clearance of
urea, t is dialysis time, and V is patient’s total body water.
Follow-up was conducted at 3, 6, 9 and 12 months. The
clinical protocol and informed consent were approved by
the Institutional Review Board at each participating site,
and all patients provided informed consent.
Bacteremia literature control. To determine a rea-
sonable expected rate of bacteremia fromTDCs, an internal
meta-analysis was performed from previous publications.
This meta-analysis of internal jugular TDC-related bacte-
remia rates was based on data published in 15 articles that
met the following criteria: prospective studies, including
prospective cohort and randomized controlled trials of
tunneled, cuffed catheters with at least 20 patients.5-19
Studies of the LifeSite Hemodialysis Access System (Vasca
Fig 1. Hemodialysis Reliable Outflow (HeRO) rightInc, Tewksbury, Mass) and Dialock Access System (BiolinkInc, Norwell, Mass) were excluded. The final normalized
cumulative TDC bacteremia control rate was 2.3/1000
catheter days.
Patency and intervention literature control. The
catheter patency literature control was based on data
published in six articles that met the following criteria:
retrospective and prospective studies of chronic hemodi-
alysis catheters for primary patency (data reported on
475 catheters at 6 months14,20-24 and 362 catheters at
12 months20-22,24), primary-assisted patency (data re-
ported on 67 catheters13), and secondary patency (data
reported on 738 catheters at 6 months14,20-24 and 591
catheters at 12 months20-22,24). The catheter patency
implant. e-PTFE, Expanded polytetrafluoroethylene.
Fig 2. Hemodialysis Reliable Outflow (HeRO) graft to outflow
component connection.literature control values were normalized.
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on the same set of articles as the catheter patency literature
control. The control value was based on the assumption
that thrombolytic treatments and secondary patency re-
quired a catheter intervention. From these articles, the
incidence of thrombolytic treatments was calculated to be
3.1 per year, and replacements were calculated to be 2.7 per
year, resulting in a catheter intervention literature control
rate of 5.8 per year.
The AVG patency literature control for primary and
secondary patency was based on a published meta-analysis
of 34 AVG studies.25 The AVG patency literature control
for primary-assisted patency was based on data published in
two articles that were randomized controlled trials of 6-mm
ePTFE grafts with 20 patients in which primary-assisted
patency data were reported.26,27 The data were normalized
for the number of participants.
The AVG intervention literature control was based on
data published in two articles that were prospective studies,
including prospective cohort and randomized controlled
trials of 6-mm ePTFE grafts with 20 patients for whom
an intervention rate was reported. The data were not nor-
malized; rather, a range of reported intervention rates was
used, resulting in an AVG intervention literature control
range of 1.6 to 2.4 per year.26,28
Adequacy of dialysis literature control. The ade-
quacy of dialysis literature control was based on a review of
retrospective and prospective articles of hemodialysis cath-
eters and grafts. This review resulted in a catheter Kt/V
control range of 1.18 to 1.46 (4399 patients)4,29-32 and
URR of 67.3% (901 patients),13,30,33,34 and an AVG Kt/V
control range of 1.37 to 1.62 (7250 patients)4,29-32 and
URR of 70.6% (4893 patients).30,34
Defining bacteremia. A HeRO device-related bacte-
remia was defined as at least one positive blood culture
(preferentially obtained from a peripheral vein), one or
more clinical manifestations of infection (ie, fever, wit-
nessed rigors, hypotension), and no other apparent source
for the bacteremia, requiring systemic treatment. This def-
inition, with the exception of the need for systemic treat-
ment, is based upon the Centers for Disease Control and
Prevention definition of catheter-related bacteremia.35
Bacteremia related to the HeRO implant procedure
was defined as any bacteremia seeded by the patient’s
previous TDC (cultured at the time of HeRO implant), any
bacteremia that might have been seeded by a pre-existing
infection elsewhere in the patient’s body (possibly making
the patient more susceptible to bacteremia in the perioper-
ative period), or any other bacteremia that occurred in the
perioperative period for which the source could not be
identified.
Bacteremia data were analyzed as a rate per 1000 days
for three cohorts:
1. The HeRO overall period, which included days from
HeRO implant to HeRO explant, ligation, or patient
death;2. The HeRO bridging period, which included HeRO
days from implant to bridging TDC removal; and
3. The HeRO alone period, which included days from
bridging TDC removal to HeRO explant, ligation, or
patient death.
Bacteremias were adjudicated by an independent Clin-
ical Event Committee (CEC), consisting of two vascular
surgeons, a nephrologist, and an interventional radiologist.
Those termed as “probably” or “definitely” related to the
HeRO device or implant procedure were considered
“HeRO-related” for analytic purposes. Bacteremias adjudi-
cated as “possibly,” “unlikely,” or “not related” were con-
sidered unrelated for analytic purposes.
Defining patency. The Journal of Vascular Surgery
reporting standards for primary, primary-assisted, and sec-
ondary patency definitions were followed.36 Primary pa-
tency was the interval from the time of access placement
until any intervention designed to maintain or re-establish
patency, access thrombosis, or the time of measurement of
patency. Assisted primary patency was the interval from the
time of access placement until access thrombosis or the
time of measurement of patency, including intervening
surgical or endovascular interventions designed tomaintain
the functionality of a patent access. Secondary patency was
the interval from the time of access placement until access
abandonment, thrombosis, or the time of patencymeasure-
ments including intervening surgical or endovascular inter-
ventions designed to re-establish functionality in a throm-
bosed access.
Defining HeRO days. HeRO days were defined as
accumulated days from HeRO implant to explant, ligation
or death. For purposes of measuring the primary end point
bacteremia rate, this is comparable to the term “catheter
days,” meaning days with an indwelling catheter as com-
monly referred to in the catheter literature.
Adverse events. Serious adverse events were defined
as events requiring hospitalization 24 hours or requiring
prolongation of an existing hospitalization, events resulting
in persistent or significant disability or incapacity, events
considered life-threatening, or events resulting in death.
All adverse events were collected. Events classified by
the investigator as serious or potentially related to the
HeRO device or implant procedure, or both, were re-
viewed by the CEC. Adverse events adjudicated by the
CEC as “probably” or “definitely” related to the HeRO
device or implant procedure were considered “HeRO-
related” for analytic purposes. Adverse events adjudicated
as “possibly,” “unlikely,” or “not-related” were considered
unrelated for analytic purposes.
Eligibility criteria. Eligible patients were those aged
21 years in ESRD requiring hemodialysis with no remain-
ing upper extremity AVF or AVG options, as identified by
vein mapping, venography, or upper extremity arterial eval-
uation, with brachial arteries 3 mm by duplex examina-
tion. Exclusion criteria were significant arterial insuffi-
ciency, ejection fraction 20%, systolic blood pressure
100mmHg, known or suspected active infection, degen-
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or hypercoagulable state, ipsilateral implantable cardio-
verter defibrillator or pacemaker, superior vena cava syn-
drome, documented drug abuse 6 months of scheduled
implant, planned concomitant surgical procedure or previ-
ous major surgery 30 days of scheduled implant, or
scheduled renal transplant 12 months.
Surgical procedure. Implantation of the HeRO de-
vice begins with introduction of the silicone outflow com-
ponent into the internal jugular vein using standard
Seldinger technique, ultrasound guidance, and fluoros-
copy. The radiopaque-enhanced distal tip of the outflow
component is positioned in the mid to upper right atrium
so that the distal outflow component tip resides at or just
beyond the superior vena cava-atrial junction when the
patient is upright. The graft component is tunneled in a
gentle C-curve along the anterolateral aspect of the upper
arm, from the brachial artery just proximal to the antecu-
bital fossa to the deltopectoral groove. The outflow com-
ponent is then attached to the titanium connector. To
complete the procedure, a graft-to-brachial artery anasto-
mosis is created in the samemanner as a conventional upper
arm ePTFE AVG.
As with all standard ePTFE grafts, the HeRO device
requires tissue incorporation before cannulation; during
this period, a bridging TDC is generally required. Once the
HeRO device is ready for cannulation, it is cannulated in
the same manner as a conventional AVG.
Statistical analysis. The study sample size, based on
the number of accumulated HeRO days, was calculated
using a one-sided, one-sample, super-superiority test on
the number of bacteremia events per 1000 HeRO days,
with an overall   0.025 and 80% power. The hypothe-
sized null literature TDC bacteremia control rate was 2.3/
1000 days (derived from the internal meta-analysis).
Assuming a HeRO-related bacteremia rate of 0.92/
1000 days, an estimated minimum 6912 HeRO days of
follow-up were required to show superiority to the TDC
bacteremia control rate.
RESULTS
A total of 38 patients were enrolled at seven sites, and
theHeRO device was successfully implanted in 36 (94.7%).
Two implant procedures were unsuccessful due to poor
brachial artery inflow or tortuous and stenotic veins that
could not be sufficiently dilated by angioplasty to accom-
modate the HeRO device. In 32 patients (89%), a bridging
TDC was required until HeRO graft incorporation. The
four patients without a bridging TDC underwent dialysis
on a failing fistula, failing graft, or received peritoneal
dialysis until successful HeRO cannulation. Of the 32
patients who required a bridging device, a femoral TDC
was used in 59%. The mean TDC bridging time, managed
according to site standard practice, was 38  21 days. The
study accumulated 9931 HeRO days (mean 276 days/
patient), with a mean follow-up of 8.6 months. No patients
were lost to follow-up.Demographics and access history. Enrolled patients
had a history of significant access challenges, including
multiple years on dialysis, multiple accesses, and a history of
bacteremia. All patients had hypertension and most were
diabetic (Table I).
Bacteremia results. Seventeen bacteremia events
were reported while a HeRO device was implanted during
a mean 8.6 months, providing an overall bacteremia rate of
1.71/1000 days. Of these 17 bacteremia events, 7 (41.2%)
were adjudicated as HeRO-related. Four of these 7 events
required HeRO device explant due to the infection. The
HeRO-related bacteremia rate was 0.70/1000 days in the
HeRO overall period (upper confidence bound rate2.3/
1000 days) which was statistically significantly lower than
the literature control (Table II). The HeRO-related bacte-
remia rate was 1.52/1000 days when the HeRO device was
placed ipsilaterally to the previous TDC and 0.30/1000
days when placed contralaterally to the previous TDC. No
HeRO-related bacteremia events occurred in the HeRO-
alone period after all bridging TDCs were removed.
The CEC adjudicated 10 of the 17 bacteremia events
(58.8%) as being related to a source other than the HeRO
device or implant procedure. In all cases, the HeRO device
showed no signs of infection, including no pus, redness, or
warmth (Table III, online only).
Patency and intervention data. HeRO device pa-
tency at a mean follow-up of 8.6 months was 38.9% pri-
mary, 86.1% assisted primary, and 72.2% secondary. The
rate of intervention for the HeRO device was 2.5 per year.
One patient was excluded from this calculation due to a
suspected hypercoagulable state, noncompliance with war-
farin, and 20 thrombectomy procedures. Refer to Table
IV for a comparison of HeRO patency and intervention
data with AVG and TDC literature.
Adequacy of dialysis. HeRO mean Kt/V was 1.7 
Table I. Demographics and access history
Variable Value
Patients, No.a 38
Years on dialysis, mean  SD (range) 5.1  4.0 (1-17)
Previous bacteremias, mean  SD (range) 1.8  0.97 (1-4)
Age, mean y 62.7
Male, % 50.0
White, % 50.0
African American, % 36.8
Hispanic, % 13.2
Diabetes mellitus, % 68.4
Coronary artery disease, % 57.9
Hypertension, % 100.0
BMI, mean  SD (range), kg/m2 29.0  7.5
Previous accesses, mean  SD (range), No. 5.4  4.3 (1-22)
Previous AVF, % (range) 65.8 (1-2)
Previous AVG, % (range) 78.9 (1-5)
Previous TDC, % (range) 100.0 (1-16)
BMI, Body mass index; SD, standard deviation.
aIncludes two enrolled patients who did not receive the Hemodialysis
Reliable Outflow (HeRO) device.0.3 (range, 1.2-2.4) andmeanURRwas 74.3 3.8 (range,
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1302 mL/min.
Adverse events. Serious HeRO-related adverse events
are presented in Table V. One patient experienced a non-
bacteremic arm infection; the HeRO device was never
cannulated and the event was possibly related to calciphy-
laxis. The CEC believed the wound would not have oc-
curred without the device being present. One patient ex-
perienced right atrial clot and probable pulmonary
embolism. This hypercoagulable individual, in whom mul-
tiple previous accesses had failed, had a history of stroke and
congestive heart failure. Warfarin was held for a period of
time due to the HeRO implant procedure, and a pulmo-
nary embolism was suspected approximately 2 weeks later.
No ventilation scan was conducted to confirm the diagno-
sis; however, there was no other obvious explanation for
noted perfusion defects given a normal chest radiograph.
The HeRO device was explanted after the diagnosis of
pulmonary embolism and right atrial clot. Even after the
HeRO device was removed, subsequent TDCs caused the
same coagulation process in this individual. All other ad-
verse events are presented in Table VI.
DISCUSSION
The HeRO device was studied in high-risk, access-
challenged patients with limited access options and compli-
cated access histories. Patients had advanced progression of
their diseases, as demonstrated by amean time on dialysis of
5.1 years (range, 1-17 years) and having undergone a mean
of 5.4 previous access procedures (range, 1-22). In addi-
tion, peripheral or central venous stenosis, or both, was
clearly evident in these patients, and 59% required a bridg-
ing femoral TDC until HeRO cannulation because no
other access sites were available. Vessel mapping, with
attention to central vein patency, confirmed the limited
access sites.
A statistically significant reduction in HeRO-related
bacteremia rates was observed in this study compared with
an internal meta-analysis of bacteremia rates from the TDC
literature. Although the device is susceptible to coloniza-
tion like other synthetic devices, its completely subcutane-
ous position decreases its infection potential. Placement of
the HeRO device in the same tract as a potentially infected
TDC can also predispose it to infection.
A higher HeRO-related bacteremia rate occurred dur-
ing the HeRO bridging period (5.10/1000 days). The
observed bacteremia rate in the bridging period likely re-
sulted because (1) a large number of patients underwent
dialysis via femoral TDCs (59%), (2) a long mean bridging
period (38, 21 days) extended the increased bacteremia
risk, and (3) the calculated rate of bacteremia was exacer-
bated due to the small sample size in this cohort (only 1373
HeRO days).
Although relatively high compared with the HeRO-
overall and HeRO-alone periods, the bacteremia rate dur-
ing the bridging period was within the range of 1.6 to 5.5
per 1000 days reported in catheter literature for internal
jugular and femoral TDCs.37Given the findings in this study, we recommend the
following measures to reduce the risk of bacteremia during
the HeRO bridging period:
● Draw blood cultures before HeRO implantation to
identify nonsymptomatic infections.
● Culture the TDC tip when removed and treat accord-
ingly based on bacteremia determination and colony
counts.
● Avoid placement of the HeRO device in previously
infected.
● Initiate prophylactic treatment during the periopera-
tive period with antibiotics based on the patient’s
bacteremia history.
● Consider prescribing prophylactic antibiotic or antimi-
crobial TDC lock.
● Consider applying antibiotic ointment to the TDC exit
site.
● Cannulate the HeRO device as soon as possible and
remove the bridging TDC.
Clinicians should anticipate a higher rate of bacteremia
when the HeRO device is placed in access-challenged pa-
tients due to their inherent increased infection risk com-
pared to graft-eligible patients. These include presence of
previous TDC fibrin sheaths and comorbidities such as
diabetes.37
The HeRO device also demonstrated improved ade-
quacy of dialysis compared with TDC literature, which
could have a significant effect on mortality rates in this
population. Each 0.1 decrease in Kt/V is associated with a
7% increase in annual mortality.38 The mean Kt/V ob-
served in this study for the HeRO device of 1.7 was
improved vs the range of 1.18 to 1.46 in the TDC litera-
ture,4,29-32 comparable to the 1.37 to 1.62 range in the
AVG literature,4,29-32 and well above the 1.4 target of the
KDOQI Adequacy of Hemodialysis Guidelines.37 Im-
proved adequacy of dialysis with the HeRO device com-
pared with TDCs was likely a result of improved blood flow
rates through the device. Observed HeRO mean blood
flow rates (1302 mL/min) were comparable to conven-
tional AVGs (1169 mL/min).39
The HeRO device secondary patency of 72.2% at 8.6
mean follow-up months and intervention rates of 2.5 per
year were comparable with the rate of 65% at 12 months
and range of 1.6 to 2.4 per year reported for conventional
AVGs. The lack of venous anastomosis and associated
neointimal hyperplasia makes it conceivable that the HeRO
device could show improved secondary patency compared
with conventional grafts in a study with longer follow-up,
where venous hyperplasia develops in a significant portion
of grafts.
The HeRO device secondary patency rates and inter-
vention rates are an improvement over those reported in
the literature for TDCs (37% at 12 months; 5.8 per year).
With continuous arterial flow and high blood flow rates
through the HeRO device compared with a TDC, fibrin
sheaths are less likely to develop at the HeRO outflow
nt, lig
nnele
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and intervention rates.
In our experience, the HeRO device provided a signif-
icant reduction (69%) in device- and procedure-related
bacteremia compared with a TDC and offered the flow,
patency, and function of a conventional AVG. Although
the HeRO device requires a surgical procedure for implant
andmore involvedmaintenance than a TDC, the advantage
of device longevity, improved adequacy of dialysis, and
significantly reduced bacteremia rates outweigh these con-
siderations for access-challenged patients. Patients with
venous obstruction who have failed previous fistulas or
grafts stand to derive the most benefit from this technol-
ogy. Thorough vessel mapping should be conducted to
Table II. HeRO-related bacteremia results
Analyzed HeRO
cohorts No. Total days
Related bacte
events
Overall 36 9931 7
Bridging period 32a 1373 7
Alone 29b 8525 0
HeRO, Hemodialysis Reliable Outflow; UCB, upper confidence bound.
aFour patients did not require a bridging tunneled dialysis catheters and recei
dialysis until the HeRO device could be cannulated.
bSeven patients did not make it to the HeRO-alone period because of expla
Table IV. HeRO patency and intervention rates vs literatu
Variable
HeRO
At 8.6
mean mon At 6 mo
Patency
Primary, % 38.9 58
Assisted-primary, % 86.1 68
Secondary, % 72.2 76
Intervention rates, y 2.5
AVG, Arteriovenous graft; HeRO, Hemodialysis Reliable Outflow; TDC, tu
Table V. Serious HeRO-related adverse events
Adverse event No. (%) (N  38)
Bleeding, hemorrhage or hematoma 2 (5.3)
Cardiac arrhythmia 1 (2.6)
Death 0 (0.0)
Edema (includes edema and swelling) 1 (2.6)
Infection (not bacteremia) 1 (2.6)
Pulmonary embolism 1 (2.6)
Right atrial clot 1 (2.6)
Steala 1 (2.6)
Stroke 0 (0.0)
Trauma to major veins, arteries, nerves 0 (0.0)
Wound problems (includes dehiscence) 1 (2.6)
HeRO, Hemodialysis Reliable Outflow.
aDefined as a persistent hypoperfusion requiring surgical intervention sup-
ported by clinical and objective evidence of ischemia. Any transient, tempo-
rary hypoperfusion that is reversible and does not require surgical interven-
tion was not considered a steal.confirm HeRO eligibility.CONCLUSION
The HeRO device offers a valuable access option for
access-challenged patients due to central venous ob-
Bacteremia
rate/1000 days UCB (97.5%)
Control rate/
1000 days
0.70 1.45 2.35-19
5.10 10.50 1.6-5.537
0.0 0.43 2.3
alysis through a failing arteriovenous fistula or graft, or underwent peritoneal
ation, or death.
literature36 TDC literature
At 12 mon At 6 mon At 12 mon
42 5014,20-24 3620-22,24
52 92%13 NR
65 5514,20-24 3720-22,24
-2.426,28 5.814,20-24
d dialysis catheter.
Table VI. All other reported adverse events
Event
N  38
Total
events
Patients with 1
event (%)
Abnormal healing/skin erosion 0 0 (0.0)
Allergic reaction 0 0 (0.0)
Bleeding 6 5 (13.2)
Cardiac arrhythmia 4 3 (7.9)
Death 13 13 (34.2)
Edema 4 4 (10.5)
Embolisma 2 2 (5.3)
Heart failure 4 3 (7.9)
Hematoma 6 5 (13.2)
Hypertension 1 1 (2.6)
Hypotension 3 3 (7.9)
Infection (not bacteremia) 24 18 (47.4)
Kinking or compression 5 5 (13.2)
Myocardial infarction 0 0 (0.0)
Other 64 30 (78.9)
Partial or full occlusion of nonstudy
device 2 1 (2.6)
Partial or full occlusion of vein or artery 1 1 (2.6)
Prosthesis technical failure 1 1 (2.6)
Pseudoaneurysm, aneurysm in graft 2 2 (5.3)
Respiratory/cardiac arrest 1 1 (2.6)
Seroma 0 0 (0.0)
Site pain 2 2 (5.3)
Trauma to major veins, arteries, nerves 0 0 (0.0)
Vascular insufficiency due to steal
syndrome 1 1 (2.6)
Wound dehiscence 2 2 (5.3)
aIncludes stroke and pulmonary embolism.remia
ved dire
AVG
n
1.6struction, with reduced bacteremia episodes and im-
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eter literature controls. Given the growth in the TDC-
dependent patient population and the morbidity and
mortality associated with catheters, this new dialysis
access device can potentially have a great impact on this
fragile patient population.
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Table III (online only). Clinical Event Committee determination of bacteremia events not related to the HeRO device
or implant procedure
Event CEC determination
1 Bacteremia was due to a urinary tract infection with white blood cells in urine indicating pyuria. The HeRO device showed no
signs of infection.
1 Bacteremia was due to community-acquired pneumonia as evidenced by radiograph. During hospitalization, patient
developed bacteremia of gastrointestinal origin (Enerococcus faecalis).
1 Likely cause was sepsis related to infarcted bowel after endovascular repair of thoracic aortic aneurysm.
1 Bacteremia was believed related to an abscess on the left upper extremity. Adjudicated as “unlikely” related to the HeRO
device and implant procedure because the graft component was healed, the patient scratched and an abscess developed
independent, presumably, of the device; fungemia developed from the abscess, and the patient continued scratching. There
was no apparent communication with the abscess and the HeRO device before the fungemia was reported. The HeRO
device was never cannulated for dialysis, therefore, the CEC determined that the HeRO device was adjacent to but did not
contribute to the abscess.
1 Bacteremia was believed related to a groin abscess, a complication due to a femoral TDC placed 1 year after HeRO implant.
1 The origin of the bacteremia could not be definitely determined. This event developed during a hospitalization in a patient
who had negative cultures upon admission. The patient had elevated WBC, evidence for disseminated intervascular
coagulation, and may have aspirated. The HeRO device showed no severe local reaction to indicate graft infection.
1 Bacteremia was related to femoral TDC placed after occluded HeRO device. Sputum, blood, and TDC tip cultured positive
MRSA. There was no evidence of infection in the HeRO device. This event was adjudicated as “not-related” to the HeRO
device or implant procedure.
1 The CEC believed the most likely source of the infection was an existing femoral TDC placed 9 days prior to HeRO implant,
or possibly the hand (knuckle wound culture positive mixed aerobic organisms); the blood cultured coagulase negative
Staphylococcus. The HeRO device showed no signs of infection and had never been cannulated. Adjudicated as “unlikely”
related to the HeRO device and “not related” to the implant procedure.
1 The CEC believed the most likely source of the bacteremia was a femoral TDC or possibly previous HeRO thrombectomy
procedure. Was adjudicated as “possibly” related to HeRO device and “not related” to the implant procedure. The HeRO
device showed no signs of infection. The patient underwent dialysis using the HeRO device for 12 months with no
infection.
1 Catheter infection associated with nontunneled central catheter that was not used for dialysis. The central catheter cultured
positive for same organism as blood. The HeRO device showed no signs of infection.
CEC,Clinical Event Committee;HeRO,Hemodialysis Reliable Outflow;MRSA,methicillin-resistant Staphylococcus aureus; STDC, tunneled dialysis catheter;
WBC, white blood cell.
